Frontier Medicines has announced the closing of a Series A Preferred Stock financing round of $67 million led by Deerfield Management, Droia Oncology Ventures and MPM Capital, with participation from DCVC Bio (an affiliated fund of DCVC), RA Capital Management and other investors, as detailed in the company’s press releas
June 26, 2019
· 1 min read